EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, G1 Therapeutics's enterprise value is $187.76 Mil.
G1 Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-34.30 Mil. Therefore, G1 Therapeutics's EV-to-EBITDA for today is -5.47.
The historical rank and industry rank for G1 Therapeutics's EV-to-EBITDA or its related term are showing as below:
GTHX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.43 Med: -2.36 Max: -0.36
Current: -5.52
During the past 9 years, the highest EV-to-EBITDA of G1 Therapeutics was -0.36. The lowest was -10.43. And the median was -2.36.
GTHX's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs GTHX: -5.52
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), G1 Therapeutics's stock price is $4.22.
G1 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.950. Therefore, G1 Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
G1 Therapeutics EV-to-EBITDA Historical Data
The historical data trend for G1 Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, G1 Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
G1 Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, G1 Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where G1 Therapeutics's EV-to-EBITDA falls into.
G1 Therapeutics EV-to-EBITDA Calculation
G1 Therapeutics's EV-to-EBITDA for today is calculated as:
G1 Therapeutics's current Enterprise Value is $187.76 Mil.
G1 Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
G1 Therapeutics's PE Ratio for today is calculated as:
G1 Therapeutics's share price for today is $4.22.
G1 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of G1 Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
G1 Therapeutics (G1 Therapeutics) Business Description
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTHX has been successfully added to your 